Bioartificial Intelligence™ Human Therapeutic Antibodies
About 200 therapeutic antibodies ('tAbs") were approved or under regulatory review in the US and Europe by the end of 2023 (Antibody Society, December 2023), each generated with in vivo platforms such as normal or human Ig transgenic animals, in vitro platforms such as phage display, or cloning from humans.
Artificial Intelligence ("AI") is increasingly being used to create tAbs via deep learning using protein and antibody "training sets" from public or private sources. Established AI models can be used to evaluate tAbs not present during the training stage or generate entirely new tAbs ("Generative AI").
Traditional tAb discovery may start with immunization of clinically and commercially proven human Ig transgenic animals, including heavy chain-only ("HCO") birds for domain antibodies ("dAbs"), followed by B cell cloning and characterization. While this alone can deliver suitable development candidates, tAbs from the B cell cloning may serve as AI training sets and lead to superior development candidates.
Abvivo's Bioartificial Intelligence™ encompasses the use of any biological information as AI input to generate mono-, bi-, and multi-specific tAbs in conventional H2L2 and other formats such as dAbs.
Abvivo's Bioartificial Intelligence™ can also be used to predict and test multi-specific dAb configurations in ways that would be practically impossible without high performance AI.
Abvivo designs, generates, and licenses its tAb development candidates to biopharmaceutical companies globally. Contact bl@abvivo.com for specific opportunities.
